Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Recruiting · NCT06569147 · Registry updated 2026-08-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Recruiting | Phase 1 / Phase 2 | 2026-08-19 | NCT06569147 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dana-Farber Cancer Institute | 324 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Brigham and Women's Hospital | Boston | United States | 511 |
| Cleaveland Clinic | Cleveland | United States | 1 |
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Tufts Medical Center | Boston | United States | 1 |
| Yale University | New Haven | United States | 352 |